Risankizumab  (Synonyms: Risankizumab rzaa; BI 655066; ABBV-066)

Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis^[1][2][3].

Human IgG1 (L234A/L235A) kappa

Human IgG1 (L234A/L235A) kappa, Isotype Control

Human

Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with K_ds <10 pM^[3].
Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC₅₀s of 2 pM and 17 pM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

51561  [NCBI]

Q9NPF7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.92 kDa

1612838-76-2

Liquid

Colorless to light yellow

[Risankizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow Cytometry analysis of Raji cells labelling IL-23A (red) with Risankizumab (anti-IL-23A) (HY-P99248). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019 Jun;79(8):893-900.  [Content Brief]

  [2]. Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy. Volume 19, 2019 - Issue 1

  [3]. Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778-91.  [Content Brief]